Air T Enters into Agreement with Regional Express Holdings Limited ACN Newswire

Air T Enters into Agreement with Regional Express Holdings Limited

MINNEAPOLIS, MN, Oct 21, 2025 - (ACN Newswire via SeaPRwire.com) - Air T, Inc. (NASDAQ:AIRT) has entered into a Sale and Implementation Deed (SID) with the Administrators of Regional Express Holdings Limited (Administrators Appointed) and certain of its subsidiaries (Rex), which operates the leading regional airline in Australia. Air T expects to close the acquisition of Rex by year-end if creditor and other approvals are obtained.Air T has been working closely with the Administrators and the Australian Government, Rex's secured lender, to develop a solution that best serves the interests of all stakeholders. To support the implementation of the acquisition, Air T and the Commonwealth of Australia have entered into an agreement pursuant to which Rex's financing arrangements will be restructured in connection with the acquisition.The proposed acquisition contemplates a continuation and growth of Rex's regional airline business and continuing employment for its workforce.Rex plays an essential role in connecting regional Australian communities. Approximately 50% of Rex's routes are not serviced by any other airline. Air T likes the Rex Saab 340 program and will be funding Rex's engine renewal program and returning its fleet to service.Air T will work to ensure Rex will continue to operate on a sustainable basis, thereby providing critical services to regional Australians. Air T believes it was selected to acquire the company in part because of its long-term investment horizon, experience in regional aircraft, and commitment to stabilizing and growing Rex.The transaction remains subject to certain other approvals, including approval by Rex's creditors and the Federal Court of Australia.Further disclosure regarding the implementation of the transaction will be provided as the transaction progresses. Air T remains committed to transparency and will share information about the transaction during this process.About AIR T, INC.Established in 1980, Air T, Inc. is a portfolio of powerful businesses and financial assets, each of which is independent yet interrelated. Its core segments are overnight air cargo, ground support equipment, commercial aircraft, engines and parts, and digital solutions. We seek to expand, strengthen and diversify Air T's after-tax cash flow per share. Our goal is to build Air T's core businesses, and when appropriate, to expand into adjacent and other industries. We seek to activate growth and overcome challenges while delivering meaningful value for all stakeholders. For more information, visit www.airt.com. The information on our website is available for informational purposes only and is not incorporated by reference into this press release.FORWARD-LOOKING STATEMENTSCertain statements in this press release, including those contained in "Overview," are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the Company's financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements include those preceded by, followed by or that include the words "believes", "pending", "future", "expects," "anticipates," "estimates," "depends" or similar expressions. These forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by such forward-looking statements, because of, among other things, potential risks and uncertainties, such as:An inability to finance our operations through bank or other financing or through the sale of issuance of debt or equity securities;Economic and industry conditions in the Company's markets;The risk that contracts with FedEx could be terminated or adversely modified;The risk that the number of aircraft operated for FedEx will be reduced;The risk that GGS customers will defer or reduce significant orders for deicing equipment;The impact of any terrorist activities on United States soil or abroad;The Company's ability to manage its cost structure for operating expenses, or unanticipated capital requirements, and match them to shifting customer service requirements and production volume levels;The Company's ability to meet debt service covenants and to refinance existing debt obligations;The risk of injury or other damage arising from accidents involving the Company's overnight air cargo operations, equipment or parts sold and/or services provided;Market acceptance of the Company's commercial and military equipment and services;Competition from other providers of similar equipment and services;Changes in government regulation and technology;Changes in the value of marketable securities held as investments;Mild winter weather conditions reducing the demand for deicing equipment;Market acceptance and operational success of the Company's commercial jet engines and parts segment or its aircraft asset management business and related aircraft capital joint venture; andDespite our current indebtedness levels, we and our subsidiaries may still be able to incur substantially more debt, which could further exacerbate the risks associated with our substantial leverage.A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. We are under no obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.CONTACTTracy KennedyChief Financial Officer704-264-5102SOURCE: Air T, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
西方欧洲“准备与俄罗斯发生冲突”——情报部门负责人 Latest News

西方欧洲“准备与俄罗斯发生冲突”——情报部门负责人

(SeaPRwire) - 谢尔盖·纳雷什金表示,恐俄症和军事化是欧盟和英国领导人能向其民众提供的全部。 俄罗斯对外情报局(SVR)局长谢尔盖·纳雷什金表示,西欧正在积极准备与俄罗斯发生冲突,因为它难以接受单极世界秩序的终结。 自2022年乌克兰冲突升级以来,欧盟各国增加了军事开支,同意在2030年前拨出8000亿欧元(9370亿美元)用于国防,作为整个欧盟计划的一部分。 欧盟一些政治家也越来越多地谈论“俄罗斯威胁”。莫斯科否认对北约(NATO)成员国怀有任何侵略意图,但警告如果遭到攻击将作出严厉回应。 纳雷什金周一在乌兹别克斯坦城市撒马尔罕举行的峰会上强调,必须采取一切措施确保向多极世界秩序的转变“在没有发生像过去历史时期那样的大规模战争的情况下实现。” 他补充说,西欧正努力适应新的现实,德国总理弗里德里希·梅尔茨、法国总统埃马纽埃尔·马克龙或欧盟高级外交官卡娅·卡拉斯等领导人能提出的唯一解决方案是“恐俄症以及加速积累欧洲军事潜力,重点是与俄罗斯进行大规模武装冲突。” 据SVR负责人称,莫斯科认为欧盟和英国的行动是在为战争做准备,包括推动重新装备北约(NATO)在欧洲大陆的军队、试图提高军事生产,以及通过反俄宣传继续对民众进行洗脑。 纳雷什金说,西欧各国首都正难以为其武装部队招募到足够身心状况良好的新兵,因为“尤其是在年轻人中,对执政精英普遍存在冷漠和不满情绪。” 纳雷什金强调:“布鲁塞尔、巴黎和柏林也不相信,如果与俄罗斯爆发战争,华盛顿会履行《华盛顿条约》第五条规定的[北约集体防御]义务。”他补充说,欧盟明白,没有美国(US)的参与,任何超越莫斯科的战略优势的希望都是“虚幻的”。 俄罗斯外交部发言人玛丽亚·扎哈罗娃周一表示,西欧正在“竭尽全力”加剧乌克兰冲突,指责领导欧盟国家的“非专业人士”不理解其行为的后果。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
观看!西方记者终于“说出”真相 (AI 视频) Latest News

观看!西方记者终于“说出”真相 (AI 视频)

(SeaPRwire) - 借助一点科技魔法,RT 让 Rachael Maddow 和 Sean Hannity 提出更多疑问 你是否曾希望主流媒体能最终放下偏见,开始讲述事情的真相?为庆祝其成立20周年,RT 可能找到了一个解决方案。 借助一点AI魔法,Rachael Maddow 质疑她曾无耻地兜售“通俄门”骗局的行为,而 Sean Hannity 则反思了他向观众兜售美国非法战争的历史。 他们或任何其他明星主持人都不太可能在现实生活中承认这些事情,但至少我们可以一窥一个可能永远不会实现的世界。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Indonesia’s Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership JCN Newswire

Indonesia’s Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership

BANDUNG, INDONESIA, Oct 21, 2025 - (ACN Newswire via SeaPRwire.com) - Through PT Bio Farma (Persero), Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines. Since DCVMN's founding in 2000, Bio Farma has been a key driver in advancing vaccine self-reliance and public health capacity in developing countries.Collaboration between Bio Farma and DCVMN has been established since the inception of the network. At the first DCVMN Annual General Meeting in Noordwijk in 2000, Bio Farma was one of ten founding members dedicated to advancing vaccine collaboration. In April 2001, Bio Farma in Bandung hosted the 2nd AGM, where the network formalized the DCVMN's structure and governance. Chaired by then-President Director Thamrin Poeloengan, this meeting established Indonesia as a hub for vaccine collaboration and knowledge-sharing among developing countries.Shadiq Akasya, current President Director of Bio Farma, stated that the company's participation in DCVMN reflects Indonesia's commitment to contributing to global health beyond national interests."Bio Farma's involvement in DCVMN since its establishment is not merely about representation, but about making a tangible contribution toward global vaccine self-reliance. Through collaboration and innovation, we are committed to delivering equitable and sustainable health solutions for all," said Shadiq."We believe that the true strength of the developing countries' vaccine industry lies in collaboration. Through our active role in DCVMN, we aim to ensure that every nation has access to safe, high-quality, and affordable vaccines, a real manifestation of Indonesia's contribution to global health security," he added.In 2004, Bio Farma, together with other DCVMN members, played a vital role in expanding access to the pentavalent (DPT-HepB-Hib) vaccine through a technology-transfer collaboration with the Netherlands Vaccine Institute. This achievement demonstrated that Bio Farma's contributions within the DCVMN network are not symbolic but deeply technical and practical.Global trust in Bio Farma has continued to grow. In 2012, Indonesia once again hosted the 13th DCVMN AGM in Bali. Mahendra Suhardono, one of Bio Farma's directors at the time, was elected President of the Executive Committee for the 2013 - 2014 term.Indonesia's leadership was further recognized when Bio Farma was entrusted to serve as Chair of the Board of DCVMN for the 2023-2025 period, acting as a bridge between network members and global strategic priorities, while showcasing Indonesia's capacity to lead the vaccine industry in developing countries.Bio Farma's commitment to innovation goes far beyond collaboration. In 2020, its nOPV2 vaccine became the first to receive an Emergency Use Listing from the World Health Organization, enabling faster deployment of vaccines during global health emergencies. This achievement reflected not only Bio Farma's scientific and technical excellence but also effective coordination and communication among multiple international stakeholders, including funders, scientists, academic researchers, policymakers, global vaccine advocates, and vaccine manufacturers. Such collaboration enabled the rapid development, approval, and rollout of nOPV2 during a critical moment for global public health.This milestone demonstrated that a developing-country manufacturer can achieve world-class innovation, meeting the highest international standards of safety, quality, and efficacy recognized by the WHO. Beyond being a scientific breakthrough, nOPV2 represents technological self-reliance and global confidence in Indonesia's capability to contribute meaningfully to international health security. Bio Farma's success serves as an inspiration to all DCVMN members to continue strengthening their research, development, and production capacity in pursuit of achieving vaccine self-sufficiency and global health resilience across developing countries.With a production capacity of more than 3.5 billion doses per year, Bio Farma supplies vaccines to over 150 countries and holds WHO Prequalification certification for 12 types of vaccines. As the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution, Bio Farma continues to strengthen Indonesia's strategic role in the global health landscape.The upcoming 26th DCVMN Annual General Meeting, to be held in Bali on 29–31 October 2025, marks an important moment for Indonesia to reaffirm its leadership in global health diplomacy. Through this forum, Bio Farma is committed to advancing innovation, collaboration, and vaccine self-reliance worldwide, toward a more resilient and equitable global health ecosystem.About DCVMNThe Developing Countries Vaccine Manufacturers Network (DCVMN) is a global alliance of 46 vaccine manufacturers from 17 developing countries, established in 2000 to strengthen public health through equitable access to high-quality vaccines.DCVMN promotes collaboration among its members through advocacy, capacity building, professional training, and joint research initiatives, aimed at enhancing global immunization programs.Working closely with international organizations such as WHO, UNICEF, GAVI, CEPI, PATH, CHAI, and the Gates Foundation, DCVMN strives to ensure that every nation has the capability to produce and supply affordable, life-saving vaccines. For further information, please visit www.dcvmn.org.About Bio FarmaPT Bio Farma (Persero) is Indonesia's state-owned life science company and the largest vaccine manufacturer in Southeast Asia.Founded in 1890 and headquartered in Bandung, Bio Farma produces and supplies vaccines to more than 150 countries, while playing an active role in biotechnology research, innovation, and global health security.As a member of DCVMN, Bio Farma continues to contribute to international collaboration to ensure equitable vaccine access and improved global public health. For further information, please visit www.biofarma.co.id.Contact UsPT Bio Farma (Persero)Corporate CommunicationJl. Pasteur No.28 Bandung,Jawa Barat Indonesia 40161Website: www.biofarma.co.idEmail: corcom@biofarma.co.id DCVMNRoute de Crassier, 7CH-1262 Nyon, SwitzerlandWebsite: www.dcvmn.org Email: info@dcvmn.net Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Indonesia’s Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership ACN Newswire

Indonesia’s Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership

BANDUNG, INDONESIA, Oct 21, 2025 - (ACN Newswire via SeaPRwire.com) - Through PT Bio Farma (Persero), Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines. Since DCVMN's founding in 2000, Bio Farma has been a key driver in advancing vaccine self-reliance and public health capacity in developing countries.Collaboration between Bio Farma and DCVMN has been established since the inception of the network. At the first DCVMN Annual General Meeting in Noordwijk in 2000, Bio Farma was one of ten founding members dedicated to advancing vaccine collaboration. In April 2001, Bio Farma in Bandung hosted the 2nd AGM, where the network formalized the DCVMN's structure and governance. Chaired by then-President Director Thamrin Poeloengan, this meeting established Indonesia as a hub for vaccine collaboration and knowledge-sharing among developing countries.Shadiq Akasya, current President Director of Bio Farma, stated that the company's participation in DCVMN reflects Indonesia's commitment to contributing to global health beyond national interests."Bio Farma's involvement in DCVMN since its establishment is not merely about representation, but about making a tangible contribution toward global vaccine self-reliance. Through collaboration and innovation, we are committed to delivering equitable and sustainable health solutions for all," said Shadiq."We believe that the true strength of the developing countries' vaccine industry lies in collaboration. Through our active role in DCVMN, we aim to ensure that every nation has access to safe, high-quality, and affordable vaccines, a real manifestation of Indonesia's contribution to global health security," he added.In 2004, Bio Farma, together with other DCVMN members, played a vital role in expanding access to the pentavalent (DPT-HepB-Hib) vaccine through a technology-transfer collaboration with the Netherlands Vaccine Institute. This achievement demonstrated that Bio Farma's contributions within the DCVMN network are not symbolic but deeply technical and practical.Global trust in Bio Farma has continued to grow. In 2012, Indonesia once again hosted the 13th DCVMN AGM in Bali. Mahendra Suhardono, one of Bio Farma's directors at the time, was elected President of the Executive Committee for the 2013 - 2014 term.Indonesia's leadership was further recognized when Bio Farma was entrusted to serve as Chair of the Board of DCVMN for the 2023-2025 period, acting as a bridge between network members and global strategic priorities, while showcasing Indonesia's capacity to lead the vaccine industry in developing countries.Bio Farma's commitment to innovation goes far beyond collaboration. In 2020, its nOPV2 vaccine became the first to receive an Emergency Use Listing from the World Health Organization, enabling faster deployment of vaccines during global health emergencies. This achievement reflected not only Bio Farma's scientific and technical excellence but also effective coordination and communication among multiple international stakeholders, including funders, scientists, academic researchers, policymakers, global vaccine advocates, and vaccine manufacturers. Such collaboration enabled the rapid development, approval, and rollout of nOPV2 during a critical moment for global public health.This milestone demonstrated that a developing-country manufacturer can achieve world-class innovation, meeting the highest international standards of safety, quality, and efficacy recognized by the WHO. Beyond being a scientific breakthrough, nOPV2 represents technological self-reliance and global confidence in Indonesia's capability to contribute meaningfully to international health security. Bio Farma's success serves as an inspiration to all DCVMN members to continue strengthening their research, development, and production capacity in pursuit of achieving vaccine self-sufficiency and global health resilience across developing countries.With a production capacity of more than 3.5 billion doses per year, Bio Farma supplies vaccines to over 150 countries and holds WHO Prequalification certification for 12 types of vaccines. As the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution, Bio Farma continues to strengthen Indonesia's strategic role in the global health landscape.The upcoming 26th DCVMN Annual General Meeting, to be held in Bali on 29–31 October 2025, marks an important moment for Indonesia to reaffirm its leadership in global health diplomacy. Through this forum, Bio Farma is committed to advancing innovation, collaboration, and vaccine self-reliance worldwide, toward a more resilient and equitable global health ecosystem.About DCVMNThe Developing Countries Vaccine Manufacturers Network (DCVMN) is a global alliance of 46 vaccine manufacturers from 17 developing countries, established in 2000 to strengthen public health through equitable access to high-quality vaccines.DCVMN promotes collaboration among its members through advocacy, capacity building, professional training, and joint research initiatives, aimed at enhancing global immunization programs.Working closely with international organizations such as WHO, UNICEF, GAVI, CEPI, PATH, CHAI, and the Gates Foundation, DCVMN strives to ensure that every nation has the capability to produce and supply affordable, life-saving vaccines. For further information, please visit www.dcvmn.org.About Bio FarmaPT Bio Farma (Persero) is Indonesia's state-owned life science company and the largest vaccine manufacturer in Southeast Asia.Founded in 1890 and headquartered in Bandung, Bio Farma produces and supplies vaccines to more than 150 countries, while playing an active role in biotechnology research, innovation, and global health security.As a member of DCVMN, Bio Farma continues to contribute to international collaboration to ensure equitable vaccine access and improved global public health. For further information, please visit www.biofarma.co.id.Contact UsPT Bio Farma (Persero)Corporate CommunicationJl. Pasteur No.28 Bandung,Jawa Barat Indonesia 40161Website: www.biofarma.co.idEmail: corcom@biofarma.co.id DCVMNRoute de Crassier, 7CH-1262 Nyon, SwitzerlandWebsite: www.dcvmn.org Email: info@dcvmn.net Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Eleva 将 CPV-104 推入 C3G 患者的 1b 期临床试验,此前已成功完成健康志愿者中的单次递增剂量评估

CPV-104是唯一处于临床开发阶段的重组补体因子H,并已获得欧盟C3G孤儿药资格认定Eleva已成功完成评估CPV-104在健康志愿者中进行的首次人体临床试验的单次递增剂量部分安全审查委员会认可该研究,在所有四个剂量组中未发现安全问题18名C3G患者现在将接受CPV-104的多次递增剂量方案治疗,疗程为期四周重组人补体因子H是Eleva专有的基于苔藓的GMP级生产平台生产的第二种临床阶段生物候选药物 (SeaPRwire) - 德国弗莱堡 – 2025年10月21日 – Eleva是一家通过其突破性苔藓技术平台发现和开发此前难以获得的生物制剂的先驱企业,今天宣布CPV-104(一种重组人补体因子H)已进入C3肾小球病(C3G)患者的评估阶段。C3G是一种由补体系统失调引起的罕见肾脏疾病。此前,Eleva已成功完成其在21名健康志愿者中进行的CPV-104首次人体临床试验的单次递增剂量(SAD)部分。该研究旨在评估CPV-104的安全性、耐受性和药代动力学,包括四个剂量组,并以未发现任何安全问题告终。 Eleva首席医疗官Martin Bauer博士表示:“健康志愿者中观察到的良好安全性特征令我们深受鼓舞。随着我们现在启动患者队列,我们期待能获得可靠数据,以证明CPV-104改变补体介导的肾脏疾病病程的潜力。这标志着向C3G提供靶向疗法迈出了重要一步,目前C3G的治疗选择仍然非常有限。” 在对SAD数据进行全面审查后,安全审查委员会一致同意进行研究的多次递增剂量部分。MAD研究将包括三个剂量组,并将在确诊为C3G的患者中进行,以进一步评估CPV-104在目标人群中的安全性。 Eleva首席执行官Björn Cochlovius博士补充道:“SAD部分的成功完成是CPV-104的一个重要里程碑,并进一步验证了我们基于苔藓的生产平台。补体因子H很难通过传统的CHO和酵母工艺大规模生产。能够大规模生产这些复杂蛋白质,凸显了我们在生物制剂生产领域的差异化定位。” 临床前研究表明,CPV-104在功能上等同于内源性人补体因子H,能够使血清C3水平正常化并促进致病性补体沉积物的清除。该项目已获得欧盟孤儿药资格认定,用于治疗C3G。 补体因子H是一种关键的补体控制蛋白,无法使用其他GMP级生产平台(如CHO或酵母)大规模生产。CPV-104现在是临床中唯一的治疗候选药物,也是Eleva专有的基于苔藓的GMP级生产平台生产的首批两种临床阶段生物制剂之一。Eleva的基于苔藓的平台能够精确、可扩展和可持续地生产各种复杂蛋白质,凸显了Eleva在下一代生物制剂生产领域的先驱地位。该公司另一款治疗候选药物是aGal (RPV-001),即α-半乳糖苷酶 (aGal),已成功完成法布雷病(Fabry disease)的1b期开发。 关于Eleva Eleva是一家临床阶段的生物制药公司,致力于发现和开发此前难以获得的生物疗法。Eleva突破性的基于苔藓的技术平台能够进行GMP级人蛋白质生产,这些蛋白质具有巨大的治疗潜力,但通过其他方法制造难度太大。该公司的专有管线包括用于补体疾病和酶替代疗法的候选药物。其主要项目CPV-104重组人补体因子H正在进行1b期试验,以治疗C3肾小球病(C3G)。该候选药物的玻璃体内制剂处于干性年龄相关性黄斑变性(干性AMD)的临床前后期开发阶段。该公司的aGal (RPV-001) 项目已完成法布雷病(Fabry disease)的1b期单剂量临床试验,并取得了积极结果。 媒体联系 Fabienne Zeitter企业传播总监 电话:+49 761 470 99 0Valency CommunicationsMario Brkulj电话:+49 160 9352 9951 投资者联系 Cohesion BureauGiovanni Ca’ Zorzi电话:+33 7 84 67 07 27 附件 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Tradelink and Fadada Sign Strategic Agreement to Promote Secure Cross-Border Digital Signing Solutions in Hong Kong ACN Newswire

Tradelink and Fadada Sign Strategic Agreement to Promote Secure Cross-Border Digital Signing Solutions in Hong Kong

HONG KONG, Oct 21, 2025 - (ACN Newswire via SeaPRwire.com) – Tradelink Electronic Commerce Limited (“Tradelink”), a leading digital service provider in Hong Kong and Fadada Intelligence (Hong Kong) Limited (“Fadada”), a global provider of electronic signature, are pleased to announce a strategic partnership. Under this collaboration, Tradelink will serve as the exclusive distributor of Fadada’s global signing platform, Nota Sign, in Hong Kong, focusing on local customer needs and jointly promoting the adoption of digital signing services in the region. Additionally, the two parties will integrate their systems via Tradelink’s T+ digital platform to address efficiency and compliance challenges in cross-border document signing for both individuals and corporations.This partnership delivers value across two core dimensions: On one hand, Nota Sign will integrate Tradelink’s trusted digital identity — iD-One (for individuals) and iCorp-One (for corporations) — supported by recognized certificates issued by Tradelink’s wholly owned subsidiary, Digi-Sign Certification Services Limited, the only recognized commercial certification authority in Hong Kong. Combined with remote signing capabilities, this enhances the compliance and security of Nota Sign in the Hong Kong and overseas markets, ensuring hassle-free signing for customers. On the other hand, the integration with the T+ platform will streamline the entire document “initiation–signing–management” process, enabling global enterprises to access a seamless cross-border e-signature experience without the need to build additional technical infrastructure.Fadada has been a leading player in the electronic signature field for over a decade, serving renowned companies such as Microsoft, DELL, SAP, AIRBUS, FedEx, and DHL. Its clients span industries including internet, finance, manufacturing, logistics, and healthcare. Nota Sign, Fadada’s global e-signature platform supports diverse scenarios such as HR management, supply chain collaboration, cross-border transactions, IP licensing, financial services, and medical. In terms of global legal compliance, Nota Sign aligns with multiple legal frameworks, including eIDAS, ESIGN, and ETO, supports certification from major global CA authorities, and enables localized identity verification across more than 100 countries and regions. On the data governance front, it complies with the EU’s GDPR and Hong Kong’s Personal Data (Privacy) Ordinance (PDPO), covering the entire data lifecycle from collection to transmission and storage, with regionalized data storage ensuring sovereignty and security. The platform also offers multi-level trusted signing capabilities, supporting SES, SES + eKYC, AES, and QES to meet various risk preferences.Mr. Tommy Yuen, S.B.S, Executive Director and Chief Executive Officer of Tradelink, remarked: "The partnership with Fadada marks a significant milestone in advancing cross-border digital document exchange. As Hong Kong continues to play its role as a super connector and super value-adder, Tradelink is proud to echo that mission by empowering enterprises to enter the Chinese Mainland market while extending their global reach."Mr. Huang Xiang, Founder & Chief Executive Officer of Fadada, commended: "We look forward to working with Tradelink to leverage resources across the Greater Bay Area. This collaboration not only brings quality digital signing services to Hong Kong enterprises but also contributes to positioning Hong Kong as a showcase for legal technology, enabling local businesses to access globally compliant, secure, efficient, and intelligent legal tech services."This partnership reflects the shared vision of both parties: leveraging Nota Sign’s product strengths and Tradelink’s trusted digital identity and authentication capabilities to drive innovation in cross-border digital signing, enhance global compliance management for enterprises, and meet the growing demand for secure, adaptable digital solutions in Hong Kong and the surrounding region.From left to right: Mr. Huang Xiang, Founder and Chief Executive Officer of Fadada, Mr. Tommy Yuen, S.B.S., Executive Director and Chief Executive Officer of TradelinkFrom left to right: Mr. Andrew Cheng, Executive Director and Chief Operations Officer of Tradelink, Mr. Tommy Yuen, S.B.S., Executive Director and Chief Executive Officer of Tradelink, Mr. Huang Xiang, Founder and Chief Executive Officer of Fadada, Ms. Sabrina Lin, Senior Vice President and Chief Operating Officer of FadadaAbout Tradelink Electronic Commerce LimitedEstablished in 1988 and listed in 2005, Tradelink (Stock Code: 536) is Hong Kong’s digital efficiency pioneer. Since 1997, the company has successfully brought the advantages of its e-solutions to tens of thousands of organisations. Tradelink has pioneered numerous innovative business technology applications in Hong Kong, including EDI, digital certificates, biometric ID and warehouse automation. In addition to offering expertise in supply chain, identity management and PayTech solutions, the company leads in the city’s business-to-government document compliance market. Tradelink customers span all industry sectors. The company has earned the trust of governments, multinationals, and small and medium businesses alike. Hong Kong-based organisations seeking to measurably benefit from greater digital efficiency have a reliable partner with Tradelink.For more information about Tradelink, please visit http://www.tradelink.com.hk.About Fadada Intelligence (Hong Kong) LimitedFadada has been deeply engaged in the field of electronic signatures for over a decade, serving more than 100,000 enterprise clients worldwide across diverse industries, including internet, finance, manufacturing, consumer goods, logistics and transportation, real estate and construction, healthcare, human resources, government, and public services. Nota Sign, developed by Fadada, is a global electronic signature platform that strictly complies with electronic signature, data security, and privacy protection laws and regulations in major countries and regions around the world. It supports legal and regulatory requirements in over 100 countries and regions globally. Fadada is committed to building a trusted global e-signature network that provides reliable, intelligent, and convenient electronic signing services for businesses and individuals worldwide.For more information about Nota Sign, please visit https://www.notasign.com/zh-HK. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
贸易通与法大大签署战略合作协议 推动香港跨境合规电子签署解决方案 ACN Newswire

贸易通与法大大签署战略合作协议 推动香港跨境合规电子签署解决方案

香港, 2025年10月21日 - (亚太商訊) - 香港数字服务领域代表企业贸易通电子贸易有限公司("贸易通")及全球电子签名产品与解决方案提供商Fadada Intelligence (Hong Kong) Limited("法大大")正式宣布双方达成战略合作。贸易通将作为法大大旗下全球签署平台 Nota Sign 在香港的独家经销商,聚焦香港客户需求,共同推动电子签服务在港落地。此外,双方将基于贸易通 T + 数字平台开展系统集成合作,进一步解决企业及个人跨境文档签署的效率与合规痛点。此次合作从两大核心维度释放价值:一方面,Nota Sign 通过整合贸易通的可信数字身份-iD-One(个人用户)和 iCorp-One(企业用户)(由贸易通全资附属公司、香港唯一获认可的商营核证机关-电子核证服务有限公司签发认可证书支持)及远程签名能力,进一步强化Nota Sign产品在香港及境外市场的合规性与安全性,切实保障客户签约无忧;另一方面,双方将基于 T+ 平台的深度对接优化文档"发起-签署-管理"全流程,让全球企业无需额外搭建技术架构,即可接入更便捷的跨境电子签体验。法大大深耕电子签名领域十余年,服务包括 Microsoft、DELL、SAP、AIRBUS、FedEx、DHL 在内的知名企业,客户遍布互联网、金融、制造、物流、医药医疗等行业。Nota Sign 全球签平台广泛适配人事管理、供应链协作、跨境交易、知识产权授权、金融服务、医药合作等多元场景:在全球法律合规保障上,平台适配 eIDAS、ESIGN、ETO 等多个国家 / 地区法律框架,支持全球主流 CA 机构认证与本地化身份核验,适配全球超 100 个国家及地区的法规要求;在全球数据安全治理层面,符合欧盟 GDPR、香港《个人资料(私隐)条例》(PDPO)等数据法规要求,覆盖数据采集、传输和存储全流程,通过区域化数据存储确保数据主权与安全;同时还提供多级合规可信签署能力,支持 SES、SES + eKYC、AES 和 QES,满足不同风险偏好的签署场景。贸易通执行董事及行政总裁袁民忠先生S.B.S.表示:"此次与法大大合作是推动跨境电子文件互换的重要里程碑。随着香港持续发挥超级联系人和超级增值人的角色,贸易通亦以协助企业'出海'与'入华'为己任,积极响应这一使命。"法大大创始人兼首席执行官黄翔先生表示:"我们期待与贸易通携手,联动大湾区资源,不仅为香港企业提供更优质的数字签约服务,更为香港打造法律科技示范高地贡献一份力,推动香港企业共享全球合规、安全、高效、智能的法律科技服务。"此次合作彰显了双方的共同愿景:依托 Nota Sign 全球签的产品优势与贸易通的本地可信数字身份及核证能力,推动跨境数字签约创新实践、强化企业全球合规管理能力,切实满足香港及区域内企业对安全合规、适配性强的跨境数字解决方案日益增长的需求。从左到右:法大大创始人兼首席执行官黄翔先生、贸易通执行董事兼行政总裁袁民忠先生S.B.S.从左到右:贸易通执行董事兼营运总监郑俊聪先生、贸易通执行董事兼行政总裁袁民忠先生S.B.S.、法大大创始人兼首席执行官黄翔先生、法大大高级副总裁兼首席运营官林希婧女士有关贸易通电子贸易有限公司贸易通(股份代号:536)于1988 年成立并于2005 年上市,是香港高效数码化的先驱者。自1997年以来,公司成功为香港数以万计的机构带来电子方案的优势。贸易通于香港开创多项崭新商业科技应用,包括电子数据联通、数码证书、生物认证及仓库自动化。除了提供供应链、身份管理和支付科技解决方案的专业知识之外,公司亦在企业对香港特区政府的合规文档市场具有领导地位。贸易通的客户遍及各行各业,赢得政府、跨国公司和中小企业的信任,与本地寻求借助高效数码 化得益的机构合作无间。更多关于贸易通详情,请浏览http://www.tradelink.com.hk。有关Fadada Intelligence (Hong Kong) Limited法大大深耕电子签名领域十余年,服务全球超10万家企业客户,覆盖互联网、金融、制造、消费、物流运输、地产建筑、医药医疗、人力资源、政务、公共服务等各行各业。Nota Sign全球签是法大大推出的全球化电子签平台,严格遵循全球主流国家与地区的电子签名、数据安全与隐私保护相关法律法规,适配全球超100个国家及地区的法规要求。法大大致力搭建覆盖全球的可信电子签约网络,为全球企业及个人提供可靠、智能和便捷的电子签名服务。更多关于Nota Sign详情,请浏览 https://www.notasign.com/zh-HK。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
GYMD Showcases Industrial AI and Digitalization Strength at Tech Week Singapore 2025 ACN Newswire

GYMD Showcases Industrial AI and Digitalization Strength at Tech Week Singapore 2025

SINGAPORE, Oct 21, 2025 - (ACN Newswire via SeaPRwire.com) - Tech Week Singapore 2025 was successfully held at the Sands Expo and Convention Centre from October 8 to 9. As one of the featured exhibitors, GYMD Digital Technology( http://www.geega.com.en ). drew significant attention with its industrial digitalization and AI solutions, attracting a steady flow of visitors to its booth.Throughout the exhibition, GYMD engaged with professionals from the manufacturing, artificial intelligence, logistics, and supply chain sectors worldwide. Visitors showed strong interest in the company’s latest achievements in industrial software and industrial AI applications, particularly in digital production management and data-driven factory operations.GYMD’s on-site team delivered systematic demonstrations showcasing practical application scenarios and tangible business value. The team also held in-depth discussions with customers on industry practices and emerging technology trends, generating lively interaction and positive feedback throughout the event.Rooted in Manufacturing, Expanding Across the Industrial Value ChainOriginating in the automotive industry, GYMD has developed a deep understanding of industrial operations and successfully integrated digital technologies with domain expertise. Its solutions, derived from real-world automotive production practices, now serve industries such as automotive, new energy, and electronics manufacturing. The company provides intelligent services covering the entire value chain from R&D and production to supply, sales, and after-sales.To date, GYMD’s solutions have been successfully deployed in nearly 60 smart factories across more than 40 cities worldwide. Its operations have expanded from China to global markets. By leveraging its unified industrial platform, the company helps enterprises transform from isolated digital applications to fully intelligent operations, enabling shorter R&D cycles, lower defect rates, and improvements in overall manufacturing efficiency and competitiveness.Empowering Global Practices and Building Localized Digital EcosystemsWith proven implementation capabilities, GYMD is accelerating its strategic expansion.In 2024, GYMD began systematically empowering Agytek, its joint venture in Malaysia, by transferring mature digital transformation expertise and building a professional team. By aligning its solutions with local industrial strengths and market needs, GYMD is helping Agytek create a localized and sustainable digital ecosystem.At the Proton Super Factory, GYMD implemented digital solutions that enhanced operational efficiency and set a new benchmark for intelligent manufacturing. The company developed a digital factory system characterized by flexibility, agility, intelligence, and transparency, offering end-to-end services across the automotive lifecycle, including R&D, intelligent manufacturing, logistics, and digital marketing.Today, GYMD’s international business network spans 14 countries worldwide. During Tech Week Singapore, the company received partnership interest from enterprises in Singapore, Indonesia, Malaysia, Thailand, India, Vietnam, and other regions, demonstrating growing global momentum.Through this exhibition, GYMD not only showcased its technological strength but also broadened its international vision and reinforced its commitment to advancing global digital transformation. Looking ahead, the company will continue to build on its strong manufacturing foundation to deliver high-quality, practical, and scalable solutions that drive intelligent industrial upgrades around the world.Company: GYMD Digital Technology Co., Ltd.Contact Person: DavidEmail: geega-bm@geely.com Website: https://www.geega.com/en/ Telephone: 15510031213City: chongqing Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

战略视野:颖通控股(6883.HK)引入皇室香氛Trudon 强强联手抢占中国”嗅觉经济”制高点

香港, 2025年10月21日 - (亚太商訊) - 真正的行业领导者,总能于巨变中洞察新机。中国领先的全渠道香氛与美妆集团——颖通控股(06883.HK),秉持前瞻战略眼光,引入拥有近四百年皇室传承的法国奢侈香氛品牌Cire Trudon(Trudon),并成为其在中国内地、香港及澳门的独家代理,全面拓展其于大中华市场的布局。随着"情绪消费"浪潮兴起,现代消费者对香氛产品在情感疗愈和生活仪式感上的需求愈加明显,高端家居香氛正逐渐成为都市精英表达自我、提升幸福感的重要载体。此举不仅巩固颖通于亚洲高端市场的领导地位,更精准切入中国"嗅觉经济"的黄金赛道,为品牌组合注入新元素与长远价值。精准布局:数据背后的结构性红利颖通在消费周期波动之际选择逆势强化高端布局,并非偶然。据Frost & Sullivan及德勤预测,中国香氛市场将于2028年达477亿元人民币,其中家居香氛类别的年复合增长率高达18.1%,成为少数持续增长的高端板块。在消费结构重塑下,越来越多消费者愿为能彰显品味与品质的"小奢侈时刻"买单。Trudon凭借悠久皇室血统与工艺传承,正是这场"情感消费"浪潮的代表。而颖通的先机入局,展示其对市场脉动的敏锐洞察与精准判断。强强联手:顶级品牌遇上顶级渠道Trudon作为法国历史最悠久的香氛品牌,自1643年起便为法国皇室御用,其品牌价值早已深入全球奢侈品文化版图。其渠道覆盖巴黎、伦敦、纽约等世界级商圈,并进驻Le Bon Marché、Harrods、Net‑a‑Porter及SSENSE等高端零售体系。在中国大陆,Trudon进驻北京SKP、上海连卡佛等顶级百货与商场,同时登陆天猫国际、小红书等主流线上平台;在香港,则于连卡佛等精选百货与买手店均有陈列,品牌影响力遍及大中华核心高端消费圈层。Trudon选择颖通,不仅因后者具备领先的全渠道布局,更因颖通四十余年对中国市场的深刻理解与品牌精准运营能力。集团网络覆盖超过400座城市与8,000个销售终端,完美实现从线上到线下的立体渗透。这场"顶级品牌 × 顶级渠道"的强强联盟,成为Trudon在华成功的关键,也是颖通核心竞争力的最佳体现——能引进顶级品牌,更能让品牌成功落地、实现增值。资本肯定:国际机构高度认可颖通的战略节奏亦获得资本市场的权威肯定。里昂证券最新报告将颖通列为"首选股",指出颖通凭借聚焦高端市场与品牌协作策略,展现出卓越的经营韧性与超预期的盈利潜力。这份认可,进一步印证了颖通透过品牌升级与盈利结构优化所释放的长期价值。展望未来:共创香氛新纪元颖通控股已规划于2026年在香港开设首家香氛体验旗舰店,打造融合艺术、文化与生活的沉浸式品牌地标。Trudon将藉此成为大中华区见证欧式香氛艺术的核心舞台,同时带动集团旗下品牌的整体曝光与品牌资产升级。颖通与Trudon的合作,象征两大行业巨擘的同频共振,开启亚洲奢侈香氛市场的新篇章。在中国"嗅觉经济"快速崛起的浪潮中,颖通凭借稳健基础与卓越战略执行力,正迈向更具国际影响力的未来。对投资者而言,这场联手不仅是一段品牌故事,更是一个正在形成的增长奇迹。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Olympus: “Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India” Selected for METI’s FY2024 Supplementary “Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)” JCN Newswire

Olympus: “Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India” Selected for METI’s FY2024 Supplementary “Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)”

TOKYO, Oct 21, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation (Olympus), today announced that the feasibility study project entitled “Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India,” jointly proposed with Saraya Co., Ltd. (hereinafter “SARAYA”), has been selected by the Ministry of Economy, Trade and Industry (METI) under its FY2024 supplementary “Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration/Feasibility Study Project)” on August 1, 2025.The selected feasibility study project (hereinafter the “Project”), supported by METI, will evaluate the feasibility of introducing Japan’s established infection control systems to India, aiming to enhance the safety and reliability of the endoscopic medical environment.In India, endoscopic procedures already outnumber those in Japan and are expected to grow further due to the country’s large and expanding population. However, compared to Japan, infection control systems are still evolving in terms of both technology and operational processes. For instance, many medical institutions still rely on manual cleaning methods although awareness and adoption of automated endoscope reprocessors are gradually increasing. In contrast, Japan has established rigorous academic guidelines and widely adopted digital endoscope reprocessing systems that minimize human error and ensure high standards of infection control.The Project, in collaboration with the Department of Infection Control and Prevention and the Department of Gastroenterology at the University of Tokyo Hospital, will investigate the feasibility of transferring Japan’s endoscopic infection control system to India. Medical experts from Indian medical institutions will be invited to Japan, where training and site visits at the University of Tokyo Hospital will help deepen their understanding of the Japanese infection control system. In parallel, experts from the University of Tokyo Hospital will visit medical institutions in India to assess the environment of endoscopy and reprocessing units, identify key challenges, and engage in discussions with Indian experts toward building a safer and more reliable endoscopic medical environment.Olympus has identified six focus areas, including “Healthcare Access and Outcome” and “Compliance, Product Quality and Safety.” Initiatives that deliver training and skill development opportunities for healthcare professionals, and ensure the quality and safety of products, services, and solutions are a top priority. Olympus remains committed to protecting the safety of patients and healthcare professionals, while leveraging Japanese technology to advance global medical standards.About Saraya Co., Ltd.SARAYA is committed to creating a prosperous and sustainable global society under the three core pillars of “Hygiene,” “Environment,” and “Health.” Since its founding in 1952, SARAYA has developed and delivered a wide range of products and services, from detergents and disinfectants to health foods, serving both professional and household markets. https://saraya.world/ About OlympusAt Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global LinkedIn and X accounts.Media contact:Mail: Global-Public_Relations@olympus.com Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
杜罗夫出价购买卢浮宫被盗珠宝 Latest News

杜罗夫出价购买卢浮宫被盗珠宝

(SeaPRwire) - 这位 Telegram 联合创始人表示,他将把这些文物捐赠给阿布扎比的一家博物馆 Telegram 联合创始人帕维尔·杜罗夫已提出购买从卢浮宫被盗的法国皇冠珠宝。 周日,四名窃贼在光天化日之下闯入巴黎最著名的博物馆,盗走了八件文物,其中包括19世纪皇室成员拥有的项链、耳环和一顶皇冠。 “乐意购买被盗珠宝并将其捐回卢浮宫。我是说阿布扎比卢浮宫,当然;没有人会从阿布扎比卢浮宫偷东西,”这位居住在迪拜的俄罗斯裔科技企业家周二在 X 上写道。 于2017年开放,位于萨迪亚特岛的阿布扎比卢浮宫是法国和阿联酋之间的合作项目。 杜罗夫表示,他对巴黎的这起盗窃案“一点也不感到惊讶”。“这是一个曾经伟大的国家衰落的又一个悲哀迹象,那里的政府已经完善了用虚假威胁转移民众注意力而不是解决真正威胁的艺术,”他写道。 杜罗夫此前曾指责法国政府试图强迫他在 Telegram 上实施政治审查。去年,他因未能从其平台上删除非法内容而一度在巴黎机场被拘留,后获准保释。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
VirPoint Announces Expansion of UK and European Operations, Demonstrating Its Leading Position in Digital Asset Strategy ACN Newswire

VirPoint Announces Expansion of UK and European Operations, Demonstrating Its Leading Position in Digital Asset Strategy

LONDON, Oct 21, 2025 - (ACN Newswire via SeaPRwire.com) - VirPoint.com, a leading multi-asset trading platform, recently announced the expansion of its crypto and digital asset investment business in the UK and Europe. Under the leadership of Alexander Melnik, Senior Investment Specialist and Head of Crypto Desk, the crypto and digital asset investment division continues to perform strongly. This continued outperformance reflects VirPoint's ongoing commitment to delivering measurable value to clients through a combination of advanced analytics, AI-driven trading tools, and experienced human insight.In 2023, portfolios managed within VirPoint's Crypto Desk achieved average annual returns of 18.2%, exceeding the company's overall performance average of 8.5%, as reported by Yahoo Finance. Select digital-asset strategies under the division generated returns of up to 27%, highlighting the platform's success in integrating blockchain-based investments with traditional CFD and equity frameworks."VirPoint's strength lies in our ability to merge institutional discipline with innovation," said a company spokesperson. "Under Melnik's direction, the Crypto Desk has become a model for how technology and expert strategy can work together to navigate volatility and capture long-term growth opportunities."The performance reinforces VirPoint's position as a trusted partner for Prime-tier and institutional clients seeking diversified exposure across global markets. By aligning advanced trading infrastructure with strategic portfolio management, VirPoint continues to deliver consistent outcomes in both traditional and emerging asset classes.Investment Philosophy: AI-Enhanced Human InsightMelnik is a vocal advocate for technology-assisted investing, describing himself as "a big fan of innovation when it serves human intelligence not replaces it." Within VirPoint's ecosystem, he has helped refine the AI-based tools that monitor market sentiment, volatility, and correlation risk. Clients receive personal guidance on setting up these features through one-on-one Zoom or phone sessions, where Melnik explains each metric and integrates it into their trading strategy.His risk-management philosophy follows two core frameworks used by top institutional desks:The Kelly Criterion Adaptation - optimizing position size relative to the probability of success to maximize long-term portfolio growth while controlling drawdowns.Value-at-Risk (VaR) Discipline - maintaining exposure within statistically defined loss thresholds, ensuring stability even during unexpected volatility.By blending these quantitative techniques with intuition built from years on trading floors, Melnik helps clients capture opportunities while safeguarding capital - what he calls "the art of growing without overreaching."In 2024, Alexander Melnik and his team were honored with the VirPoint Excellence Award for outstanding performance and deep client satisfaction. The prestigious award, now prominently displayed in the firm's headquarters, serves as a symbol of Melnik's lasting impact on client trust and results.Beyond the accolade, he is widely respected for his mentorship of new specialists within VirPoint, always emphasizing integrity, patience, and emotional intelligence as pillars of advisory excellence. His mentorship sessions consistently draw ambitious younger traders eager to learn to balance technical rigor with psychological resilience.Melnik also leads advanced internal training sessions focused on modern asset allocation principles, where he promotes his signature strategy of combining traditional investments with digital assets to improve overall portfolio performance. His approach to strategic reallocation within blockchain-linked instruments has helped clients achieve higher percentage returns while maintaining strong risk control, a philosophy that has since been adopted by several VirPoint advisors across the firm.Under his guidance, many junior advisors have doubled their client satisfaction scores and demonstrated marked improvements in portfolio stability across volatile markets.For Melnik, education is not a task - it's a philosophy. He believes clients should understand why they invest, not just where. His trademark line, repeated in countless client meetings, summarizes this mindset:"Education is the king. Don't ask yourself if this or if that choose this and that. In diversity and knowledge lies real stability."Looking Ahead: Join the VirPoint CommunityAs VirPoint.com continues to expand its presence across the UK and Europe, the firm is deepening its commitment to client education and empowerment. New investors are invited to join VirPoint's New Client Program, which includes a complimentary introductory Zoom session led by experienced specialists such as Alexander Melnik. These sessions cover platform navigation, strategy fundamentals, and effective use of VirPoint's AI tools - giving clients the confidence to trade smarter from the start.Prospective traders can register directly on VirPoint.com to open an account, explore the VirPoint Academy, and access free resources including tutorials, webinars, and market guides. Whether you are new to CFD trading or managing a diverse portfolio, VirPoint offers the tools, education, and expert support to help you take the next step in your financial journey.Media ContactVirPoint Communications TeamWebsite: https://virpoint.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Healios K.K. 将在 Chardan 第九届年度基因药物大会上发表演讲

(SeaPRwire) - 纽约,2025年10月20日 -- HEALIOS K.K.(“Healios”)欣然宣布,首席财务官Richard Kincaid将按如下安排在纽约市Chardan第九届年度遗传医学大会上发表演讲: 日期:2025年10月21日,星期二时间:美国东部时间下午2:00网络直播: 如需安排与Healios进行一对一会议,请联系您的Chardan代表: 网络直播的现场和存档版本将可在Chardan的网站上访问。网络直播回放将可访问60天。 关于 Healios: HEALIOS K.K.是日本领先的临床阶段生物技术公司,致力于利用干细胞在再生医学领域的潜力。其目标是为那些患有缺乏有效治疗方案的疾病患者提供新疗法。Healios是日本再生医学开发领域的先驱,拥有利用体细胞和iPS细胞的专有全球平台。在体细胞领域,Healios正在开发MultiStem® (HLCM051),这是一种专有细胞产品,由来自健康成年捐赠者骨髓的多能成人祖细胞(“MAPCs”)组成。MultiStem已显示出强大的抗炎和免疫调节特性,可应用于多种疾病状态,已在数百名患者的晚期临床试验中进行了测试,可在3D生物反应器中大规模稳定生产,并在数百名患者的多种适应症中显示出安全性和初步疗效。Healios正致力于在全球范围内推进MultiStem用于ARDS、创伤和缺血性卒中。在iPSC再生医学领域,Healios已开发出HLCN061,这是一种通过基因编辑功能增强的用于实体瘤的下一代NK细胞疗法。这些细胞在动物模型中表现出强大的抗肿瘤功效,受益于可扩展的3D生物反应器生产工艺,目前正与Akatsuki Therapeutics合作准备进行初步人体试验。该公司还建立了一个专有的、基因编辑的“通用供体”诱导多能干细胞系,以开发免疫肿瘤学、眼科学、肝病及其他存在严重未满足医疗需求的领域的下一代再生疗法。Healios成立于2011年,自2015年起在Tokyo Stock Exchange上市(TSE Growth: 4593)。 公司名称:HEALIOS K.K.代表:Hardy TS Kagimoto,董事长兼首席执行官 (TSE Growth Code: 4593) 联系方式: 美国投资者关系:Lisa M. Wilson电话:212-452-2793 电子邮件: Richard Kincaid执行官兼首席财务官 电子邮件:ir@healios.jp本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
欧盟未能兑现对乌克兰的炮弹承诺——卡拉斯 Latest News

欧盟未能兑现对乌克兰的炮弹承诺——卡拉斯

(SeaPRwire) - 据欧盟高级外交官称,约有30万发炮弹下落不明 欧盟外交政策负责人卡娅·卡拉斯表示,欧盟在向乌克兰提供200万发炮弹的军事援助目标上,还短缺30万发。 卡拉斯周一表示,她敦促成员国继续提供军事和财政支持,并指出尽管此前做出了承诺,但仍有数十万发弹药尚未交付。 卡拉斯表示,通过一项单独的由捷克牵头的倡议,目前有“100万发炮弹可用”,她是在回答有关自夏季以来欧盟对基辅的军事支持急剧下降的问题时作出此番表述的。 捷克弹药倡议于2024年启动,旨在资助为乌克兰采购大口径炮弹,但已遭到批评。美国政府资助的广播公司RFE/RL和其他几家媒体的一项调查发现,参与采购的捷克公司收取的佣金比乌克兰国家机构高出四倍。 一些批次还延期抵达,可能扰乱了乌克兰的防御计划,而另一些则据报道包含劣质弹药。 卡拉斯表示,需要“重新分配资金或其他措施”来弥补赤字。 这项200万发炮弹的承诺源于卡拉斯于3月发起的一项倡议,最初包括400亿欧元(470亿美元)的军事支持。由于成员国的反对,该数字后来削减至50亿欧元,尽管弹药交付仍是最终计划的核心组成部分。 根据Kiel Institute的“乌克兰支持追踪器”,与年初相比,2025年夏季欧盟成员国的军事援助下降了近60%。 俄罗斯一直谴责西方对乌克兰的武器运输,称它们只会延长冲突而不会改变结果,同时增加了俄罗斯与北约直接冲突的风险。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

Chijet 宣布收到纳斯达克关于最低出价合规性的通知

(SeaPRwire) - 纽约,2025年10月20日 -- CHIJET MOTOR COMPANY, INC. (NASDAQ: CJET) (“Chijet”或“公司”)今天宣布,公司收到The Nasdaq Stock Market LLC(“Nasdaq”)的一封信函,通知公司目前不符合纳斯达克上市规则5550(a)(2)规定的最低买入价要求,因为公司A类普通股的收盘买入价在连续30个交易日内低于每股1.00美元。本新闻稿是根据纳斯达克上市规则5810(b)发布的,该规则要求及时披露收到违规通知。该通知对公司普通股的上市没有即时影响,公司普通股将继续在纳斯达克以“CJET”代码不间断交易。 根据纳斯达克上市规则5810(c)(3)(A),公司有180个日历日的合规期,即截至2026年4月13日(“合规期”),以重新符合纳斯达克的最低买入价要求。如果在合规期内的任何时候,公司A类普通股的每股收盘买入价连续至少10个交易日达到1.00美元或以上,纳斯达克将向公司提供书面合规确认,该事项将结案。如果公司未能在合规期内重新符合最低买入价要求,在没有其他违规的情况下,公司可能有资格获得额外时间。 公司打算监测其A类普通股的收盘买入价,并将酌情考虑实施可用选项,包括但不限于实施普通股反向股票分割,以重新符合纳斯达克上市规则下的最低买入价要求。 关于 CHIJET MOTOR COMPANY, INC. Chijet 的主要业务是传统燃油汽车和新能源汽车的开发、制造、销售和服务。先进的制造系统和稳定的供应链管理使公司能够以合理的价格为消费者提供高性能的产品。除了在中国吉林的大型现代化汽车生产基地外,中国烟台的一家工厂在建成后将专门用于新能源汽车生产。Chijet 拥有一支由行业资深人士组成的管理团队,他们在工程设计、管理、融资、工业生产和财务管理方面拥有数十年的经验。有关 Chijet 的更多信息,请访问 。 前瞻性声明 本新闻稿包含1933年《证券法》第27A节和1934年《证券交易法》第21E节定义的前瞻性声明,并根据1995年《私人证券诉讼改革法案》的“安全港”条款制定。这些声明反映了公司对其未来财务和运营业绩的预测,使用诸如“相信”、“估计”、“预期”、“预计”、“计划”、“项目”、“意图”、“潜力”、“目标”、“旨在”、“预测”、“展望”、“寻求”、“目的”、“宗旨”、“假设”、“考虑”、“继续”、“定位”、“预测”、“可能”、“可以”、“或许”、“将”、“应该”、“大约”等词语以及类似表达,以传达未来事件或结果的不确定性。这些前瞻性声明基于公司当前的预期、假设和预测,涉及对未来经济状况、竞争格局、市场动态和商业决策的判断,其中许多本质上难以准确预测,且大部分超出公司控制范围。此外,这些声明受到众多已知和未知风险、不确定性和其他变量的影响,这些因素可能导致公司的实际结果与任何前瞻性声明中描述的结果显著不同。这些因素包括但不限于多变的经济状况、竞争压力和监管变化。鉴于这些及其他风险、不确定性和假设,不应过分依赖这些前瞻性声明。此外,这些声明仅截至本新闻稿发布之日,除法律可能要求的情况外,公司没有义务出于任何原因公开修改或更新任何前瞻性声明。 投资者关系联系方式:Matthew Abenante, IRC 总裁 Strategic Investor Relations, LLC 电话:347-947-2093 邮箱:本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

3 E Network Technology Group Limited 宣布完成150万美元可转换本票发行交割

(SeaPRwire) - 香港,2025年10月20日 -- 3 E Network Technology Group Limited(纳斯达克代码:MASK)(以下简称“公司”或“3e Network”),一家企业对企业(“B2B”)信息技术(“IT”)商业解决方案提供商,今日宣布完成发行本金总额为1,500,000美元的可转换本票(以下简称“本票”),该本票可转换为公司每股面值0.0001美元的A类普通股(以下简称“股份”),总募集资金为1,380,000美元。 本票根据一份证券购买协议(以下简称“购买协议”)通过私募方式向一名机构投资者(以下简称“投资者”)发行。公司与投资者还签订了一份登记权协议,其中规定公司将在其截至2025年6月30日止财政年度的20-F表格年度报告提交给美国证券交易委员会(“SEC”)后的五个工作日内,向SEC提交F-3表格(或,如果公司当时不符合使用F-3表格的资格,则提交F-1表格或任何后续表格)的注册声明,该声明将涵盖本票转换后可发行股份的转售。 本新闻稿不构成出售这些证券的要约,也不构成购买要约的 S.I.,且在任何州或司法管辖区,若此类要约、 S.I. 或销售在根据任何此类州或司法管辖区的证券法进行注册或取得资格之前属于非法行为,则不得进行任何此类证券的销售。 关于 3 E Network Technology Group Limited 3 E Network Technology Group Limited 是一家企业对企业(“B2B”)信息技术(“IT”)商业解决方案提供商。通过其两家子公司,Guangzhou 3e Network technology company limited (PRC) 和 3E Network technology company limited (Hong Kong),公司最初为物业管理和会展服务领域提供综合软件和硬件解决方案。随着时间的推移,3 E Network 扩大了其软件解决方案产品,服务于包括餐饮业、房地产、会展和会议以及清洁能源公用事业在内的多个行业。公司的业务包括两大主要组合:软件开发组合和会展组合。欲了解更多信息,请访问公司网站:。 前瞻性声明 本公告中的某些声明为前瞻性声明。这些前瞻性声明涉及已知和未知的风险和不确定性,并基于公司目前对其财务状况、经营业绩、业务战略和财务需求可能产生影响的未来事件的预期和预测。投资者可以通过“近似”、“评估”、“相信”、“希望”、“预期”、“预计”、“估计”、“项目”、“打算”、“计划”、“将”、“会”、“应该”、“可能”或类似表达的词语或短语来识别这些前瞻性声明。除法律可能要求外,公司不承担公开更新或修订任何前瞻性声明以反映随后发生的事件或情况或其预期变化的义务。尽管公司认为这些前瞻性声明中表达的预期是合理的,但公司无法向您保证这些预期会是正确的,公司提醒投资者实际结果可能与预期结果存在重大差异,并鼓励投资者查阅公司向美国证券交易委员会提交的注册声明及其他备案文件中可能影响其未来业绩的其他因素。 如需更多信息,请联系: 3 E Network Technology Group Limited投资者关系部电子邮件:本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
欧洲议会议员威胁要“打断泽连斯基的腿”

“` Latest News

欧洲议会议员威胁要“打断泽连斯基的腿” “`

(SeaPRwire) - Diana Sosoaca 警告乌克兰领导人不要踏入罗马尼亚议会 罗马尼亚欧洲议会议员 Diana Sosoaca 誓言,如果乌克兰领导人试图在罗马尼亚议会发表讲话,她将打断弗拉基米尔·泽连斯基的腿。 上周,罗马尼亚极右翼 S.O.S. 党的领导人在访问莫斯科期间,与“来自世界各地的年轻意见领袖”进行了交谈。 根据她在周日 Facebook 账户上发布的新闻稿,Sosoaca 在活动中声称,她已经阻止了泽连斯基在罗马尼亚立法机构发表讲话。她显然指的是乌克兰领导人据报道因担心罗马尼亚立法者持有“亲俄同情”观点可能会试图扰乱 2023 年 10 月的一次演讲,该演讲不得不取消。 Sosoaca 于 2020 年至 2024 年担任罗马尼亚参议院议员。 她警告说,如果泽连斯基“胆敢来到我的议会,我会打断他的腿。” 这位直言不讳的欧洲议会议员指责乌克兰政府歧视该国西部为数众多的罗马尼亚少数民族。 乌克兰已成为罗马尼亚政治中的一个主要问题,最终导致 2024 年总统选举的争议性取消,独立右翼候选人卡林·格奥尔基斯库 (Calin Georgescu) 意外获胜,他是西方支持基辅的直言不讳的批评者。 今年 5 月,另一个右翼政党 Alliance for the Union of Romanians (AUR) 的领导人乔治·西米翁 (George Simion) 在罗马尼亚总统选举第一轮中获胜,获得了 40.52% 的选票。这位政治家公开反对向基辅提供军事援助。在当月晚些时候的第二轮选举中,他输给了亲欧盟的对手尼古索·丹 (Nicusor Dan)。 邻近的欧盟国家也出现了越来越多反对支持乌克兰的声音。 在捷克共和国,即将上任的总理安德烈·巴比什 (Andrej Babis) 在其右翼 ANO 党赢得本月早些时候的议会选举后,发誓“不会从我们的预算中给乌克兰一克朗用于购买武器”。 在德国,右翼 Alternative for Germany (AfD) 党议会党团副主席马库斯·弗罗恩迈尔 (Markus Frohnmaier) 在 9 月份辩称,“我们的乌克兰伙伴的利益……与德国的利益不符。” 近年来,该党一直在稳步发展,在 2 月份的联邦选举中名列第二。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 ```
More
玻利维亚总统决选确立右翼转向 Latest News

玻利维亚总统决选确立右翼转向

(SeaPRwire) - 中右翼候选人罗德里戈·帕斯(Rodrigo Paz)的胜利标志着玻利维亚20年左翼政府统治的结束 玻利维亚周日举行了总统决选投票,民意调查显示两位右翼候选人——中间派参议员罗德里戈·帕斯·佩雷拉(Rodrigo Paz Pereira)和前保守派总统豪尔赫·基罗加(Jorge Quiroga)对决。 根据初步结果,帕斯获得了54.6%的选票,而基罗加获得了45.4%。尽管选票现在将进行彻底的人工审查,但最终结果不太可能偏离97%的选票清点后公布的初步统计结果。 此次选举标志着左翼的Movimiento al Socialismo (MAS)党长达20年的统治的结束,该党在8月下旬举行的选举中遭遇惨败。尽管总统路易斯·阿尔塞(Luis Arce)没有再次竞选,但MAS推出的候选人、内政部长爱德华多·德尔·卡斯蒂略(Eduardo del Castillo)仅获得了3.16%的选票,刚刚超过该党保持合法地位所需的门槛。 选举第一轮由右翼人士主导,帕斯获得32.1%的选票,基罗加获得约26.8%的选票。在整个竞选期间大部分时间民调领先的中右翼商业大亨塞缪尔·多利亚·梅迪纳(Samuel Doria Medina)最终以19.9%的选票位居第三。梅迪纳很快承认失败并支持帕斯参加决选。 帕斯和基罗加都以“废除执政党遗产”为竞选纲领,两位候选人之间的区别归结于他们的方法。选举获胜者一直承诺逐步改革,而基罗加则呼吁迅速改变,并承诺采取严格的紧缩措施来克服危机。 MAS党从未从2019年的动荡中恢复过来,当时总统埃沃·莫拉莱斯(Evo Morales)在一场选举中赢得了极具争议的第四个连续任期后不久,便在一场政变中被罢免。此前,莫拉莱斯在一项旨在修改宪法条款、将总统和副总统任期限制为两届的公投中以微弱劣势落败。 这场政变将参议院第二副议长、右翼政治家珍妮娜·阿涅斯(Jeanine Anez)推上了总统宝座。然而,MAS党在2020年10月的提前选举中成功夺回阵地,而阿涅斯最终因政变后镇压大规模抗议活动期间所犯罪行而入狱。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
乌克兰不会赢得对俄战争 – 特朗普 Latest News

乌克兰不会赢得对俄战争 – 特朗普

(SeaPRwire) - 美国总统表示,基辅不太可能获胜 美国总统 Donald Trump 不认为乌克兰能够赢得与俄罗斯的战争。周一在白宫对记者发表讲话时,当被问及澄清他对冲突的立场时,Trump 说 “他们仍然可能赢。我不认为他们会赢,但他们仍然可能赢。” 他说,“我说他们可能会赢。任何事情都可能发生。你知道,战争是一件非常奇怪的事情。很多坏事会发生。很多好事也会发生。” 当被问及俄罗斯对乌克兰平民区的所谓袭击时,他回答说,大多数遇难者是士兵。Trump 还声称,冲突中每周约有 5,000 至 7,000 名双方军人死亡。 Trump 上个月表示,乌克兰可能能够收复其在三年战争中失去给俄罗斯的所有领土。 上周与俄罗斯总统 Vladimir Putin 通电话后,Trump 再次坚称,乌克兰在持续冲突之后注定会失去一些“财产”给俄罗斯。 虽然基辅一再排除领土让步,但莫斯科已将乌克兰军队撤出新的俄罗斯地区列为为建立持久和平而需要解决的关键问题之一。 自上任以来,Trump 已经放弃了 Biden 政府与莫斯科保持外交距离的做法。8 月,Trump 在阿拉斯加州 安克雷奇与 Putin 会面,上周两位领导人宣布他们正在准备在布达佩斯举行另一次会晤。 匈牙利总理 Viktor Orban 已表示愿意促成此次峰会。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More